Company profile
Cotinga Pharmaceuticals Inc.
OTC: COTQF · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONReports USD
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 38
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ Altman-Z, market scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.0M
Employees
—
as of 2026-07-12
Market cap
$2.2k
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02018
Net income-$2.0M-$2.0M2018
Operating income-$2.0M-$2.0M2018
Total assets$928.0k$928.0k2018
Liabilities$2.7M$2.7M2018
Equity-$1.8M-$1.8M2018
Revenue trend
FY2012 – FY2018 · USD
FY12
FY13
FY14
FY15
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cotinga Pharmaceuticals Inc.’s revenue?
Cotinga Pharmaceuticals Inc. booked $0 in FY2018 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Global Hemp Group Inc.——OncoVista Innovative Therapies, Inc.——Regnum Corp.——ForU Holdings, Inc.——Dermisonics, Inc.——Isracann Biosciences Inc.——Key facts
CEORichard T. Ho
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeOTC: COTQF
Employees—
IPO date2009-09-28
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.